KNE Kane Biotech Inc.

Kane Biotech Secures IRB Approval to Launch Innovative DispersinB® Acne Trial

Kane Biotech Secures IRB Approval to Launch Innovative DispersinB® Acne Trial

Kane to work with the University of Miami to study DispersinB® Acne Cleanser in mild to moderate Acne Vulgaris

WINNIPEG, Manitoba, March 13, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) ("Kane Biotech" or "Kane") announces today that it has received approval from the Internal Review Board (“IRB”) of the University of Miami Health System (“UHealth”) to commence a clinical study of Kane’s prototype DispersinB® Acne Cleanser for the treatment of mild to moderate cases of Acne Vulgaris.

The title of the study is “Split-face efficacy and tolerability of DispersinB® Acne Cleanser in the treatment of mild to moderate Acne Vulgaris.” The trial, which is expected to commence by mid-year, will be conducted on up to 24 subjects and will take place at the University of Miami Miller School of Medicine. The Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery at the University of Miami Health System is recognized as a global leader in caring for conditions and disorders of the skin.

“We are thrilled to receive approval from the UHealth's IRB to move forward with our trial for DispersinB® in the treatment of acne," said Marc Edwards, President & CEO of Kane Biotech. "DispersinB® represents a groundbreaking approach to tackling acne, and we believe it has the potential to significantly improve outcomes for millions of people struggling with this condition. This approval marks an important milestone as we continue advancing our mission to bring innovative, science-driven dermatological solutions to market."

About Kane Biotech

Kane Biotech Inc. is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. Kane has a portfolio of biotechnologies, intellectual property (66 patents and patents pending as well as trade secrets and trademarks) and products developed by Kane's own biofilm research expertise and acquired from leading research institutions. DispersinB®, coactiv+™, coactiv+®, DermaKB™, DermaKB Biofilm™, and revyve™ are trademarks of Kane Biotech Inc. Kane is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF”.

About UHealth – University of Miami Health System

UHealth – University of Miami Health System delivers leading-edge patient care by top-ranked physicians who treat some of the most complex cases. Powered by the Miller School of Medicine’s ground-breaking research and medical education, UHealth is the region’s only academic-based health care system. With a comprehensive network of nearly 40 outpatient facilities, its flagship hospital in the heart of Miami’s Health District, and more than 2,700 providers across South Florida, UHealth is a vital component of the community that is leading the next generation of health care. UHealth is home to Bascom Palmer Eye Institute, the No. 1 ranked eye hospital in the nation by U.S. News & World Report, Sylvester Comprehensive Cancer Center, the region’s only NCI-designated cancer center, and Desai Sethi Urology Institute, dedicated to urologic research and discovery, and a neurology and neurosurgery program ranked in the top 25 in the nation. These programs along with 100 other specialties make UHealth a trusted destination for compassionate, research-based care.

     

For more information:

Marc EdwardsRay Dupuis
Chief Executive OfficerChief Financial Officer
Kane Biotech IncKane Biotech Inc
  

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Information

This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to Kane’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of Kane to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by Kane with applicable securities regulatory authorities, available at . Kane cautions that the foregoing list of factors that may affect future results is not exhaustive.



EN
13/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Kane Biotech Inc.

 PRESS RELEASE

Kane Biotech Completes U.S. FDA 510(k) Submission for revyve® Antimicr...

Kane Biotech Completes U.S. FDA 510(k) Submission for revyve® Antimicrobial Wound Cleanser WINNIPEG, Manitoba, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or the “Company”) today announces that it has completed a U.S. Food and Drug Administration (“FDA”) 510(k) clearance submission for its revyve® Antimicrobial Wound Cleanser. revyve Antimicrobial Wound Cleanser is the Company’s third product in its revyve product line and complimentary to Kane’s revyve Antimicrobial Wound Gel and Antimicrobial Wound Gel Spray products. This new companion product will...

 PRESS RELEASE

Kane Biotech Completes Enrollment in U.S. Case Series Studies of its r...

Kane Biotech Completes Enrollment in U.S. Case Series Studies of its revyve® Antimicrobial Wound Gel and Spray WINNIPEG, Manitoba, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or “Kane”) today announces that it has enrolled 28 participants in its revyve® Antimicrobial Wound Gel and Spray U.S. Case Series Studies, exceeding its 25-participant target. US FDA 510(k) cleared revyve Antimicrobial Wound Gel For the clinical series, Kane engaged wound care and burn specialists in the U.S. Data is anticipated to be presented at various medical m...

 PRESS RELEASE

Kane Biotech to Present revyve® Clinical Data at Symposium on Advanced...

Kane Biotech to Present revyve® Clinical Data at Symposium on Advanced Wound Care (SAWC) Fall Conference Clinical data to be presented demonstrates wound healing in complex wounds that were over two years old WINNIPEG, Manitoba, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces that Interim Chief Executive Officer, Dr. Robert Huizinga, will be presenting at the Symposium on Advanced Wound Care (“SAWC”) Fall conference taking place from September 3-6, 2025 in Las Vegas, Nevada. US FDA 510(k) cleared revyve An...

 PRESS RELEASE

Kane Biotech Announces Second Quarter 2025 Financial Results

Kane Biotech Announces Second Quarter 2025 Financial Results WINNIPEG, Manitoba, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announced its second quarter 2025 financial results. Second Quarter 2025 Financial Highlights (Comparatives exclude discontinued STEM Animal Health “STEM” Operations): Total revenue for the three months ended June 30, 2025 was $27,997 compared to $620,437 in the three months ended June 30, 2024. Almost all revenue recorded in the comparative quarter was related to the Company’s animal health busin...

 PRESS RELEASE

Kane Biotech Showcases revyve™ Preclinical and Clinical Case Study Fin...

Kane Biotech Showcases revyve™ Preclinical and Clinical Case Study Findings at North American Wound Care Conferences Clinical case series showed clinically meaningful reductions in wound size and pain, and improved tissue regranulation in chronic wound patients using revyve® over 6–12 weeks Preclinical in vitro studies demonstrated >80% reduction in protease activity, including complete inhibition of TACE and collagenase — key factors in non-healing chronic wounds revyve® data featured in presentations and posters at NSWOCC and SAWC—two of the leading North American conferences on wound c...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch